 Ginkgo Bioworks, a biotech company based in Boston, announced that it will go public via a merger with Soaring Eagle Acquisition Corp. SRNG, a special purpose acquisition vehicle SPAC, in a deal that gives the company a pre-money equity valuation of 15 billion. The company expects to receive proceeds of 2.5 billion as part of ... The post Ginkgo Bioworks to go public in a 15B SPAC deal appeared first on Invezz. 